Clinical trial
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
NCT02177071 is registered in ClinicalTrials.gov with Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
- Lead sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 9, 2015
- Completion date
- October 31, 2021
- Enrollment
- 211 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease